A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA)

Name: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA)
Creator: Vivli
Published: 2025-06-01 01:03:43
License: 暂无描述

DataCite Commons2025-06-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00009901/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

提供机构：

Vivli

创建时间：

2024-03-20